The HIV positive selection mutation database is a large-scale database available at http://www. bioinformatics.ucla.edu/HIV/ that provides detailed selection pressure maps of HIV protease and reverse transcriptase, both of which are molecular targets of antiretroviral therapy. This database makes available for the first time a very large HIV sequence dataset (sequences from $50 000 clinical AIDS samples, generously contributed by Specialty Laboratories, Inc.), which makes possible highresolution selection pressure mapping. It provides information about not only the selection pressure on individual sites but also how selection pressure at one site is affected by mutations on other sites. It also includes datasets from other public databases, namely the Stanford HIV database
INTRODUCTION
The HIV-1 virus is the causative agent of AIDS, a growing worldwide epidemic and also a fascinating system for studying fundamental scientific questions. For example, one major clinical problem in the treatment of AIDS is HIV's ability to develop resistance to antiviral drugs rapidly, often within weeks of introduction of a new drug (1) (2) (3) . Foremost among the factors responsible for this are the virus' extremely high mutation rate (4, 5) and replication rate (3, (6) (7) (8) . For this reason, there is great medical interest in understanding both the specific causes of drug resistance, and predicting fast versus slow evolutionary pathways to multiple drug resistance. At the same time, HIV provides an extraordinary wealth of data about fundamental scientific questions such as the fitness landscape for protein evolution (9, 10) .
*To whom correspondence should be addressed. Tel: +1 310 825 7374; Fax: +1 310 206 7286; Email: leec@chem.ucla.edu from $50 000 clinical AIDS samples), which makes possible high-resolution selection pressure mapping, as well as smaller datasets from other public databases. The methods and most of the data described herein have been published previously (12, 18) .
DATABASE CONTENT, INTERFACE AND APPLICATIONS

Datasets
The primary dataset consists of sequences for HIV protease and reverse transcriptase (RT) for $50 000 clinical AIDS patient samples from the United States, collected during 1999-2003 (12) , and mostly under drug treatment. These data cover 1.4 kb each [300 000 chromatograms; six overlapping reads per sample, including both strands; see (12) for details] and were generously contributed by Specialty Laboratories Inc. Owing to HIV's high mutation rate, on average each sequence contains 32 mutations/kb [with respect to the Los Alamos reference sequence (12) ], for a total of more than 2 million mutation observations in the dataset (12) . Over 5000 distinct codon mutations were observed, each with an average count of 364 samples (12) . For comparison, this density of polymorphism information is equivalent to sequencing $1 million people. This very large dataset, made available publicly for the first time, has made detailed selection pressure mapping possible. Of the samples, 99.3% are subtype B; non-subtype-B samples were excluded from the analysis (12) . The dataset is fully HIPAA-compliant; all information concerning the source patients was removed by Specialty.
The database currently includes two additional datasets, also covering HIV protease and RT. These datasets were obtained from the Stanford HIV database (19) . The StanfordTreated dataset consists of 1797 subtype B samples with known drug treatments. This dataset provides a useful comparison with the Specialty results, for validating whether a specific mutation is reproducibly selected by drug treatment. The Stanford-Untreated dataset consists of 2628 subtype B samples not under drug treatment. By comparing results from this dataset with Specialty and Stanford-Treated, users can assess whether a specific mutation is more likely to be associated with drug resistance or other types of phenotypic fitness effects (e.g. interactions with the immune system).
The Specialty raw sequence data are available as a gzip'ed FASTA file at http://www.bioinformatics.ucla.edu/ HIV/Specialty_sequences.fasta.gz.
Amino acid selection pressure mapping
The first aspect of the database is mapping of K a /K s selection pressure at each codon position in HIV protease and the first 381 codon positions of RT (Figure 1 ). Further positions in RT were not sequenced in this dataset. Codon-specific selection pressure (12) was calculated using the following formula:
where N a and N s are the number of amino acid mutations and synonymous mutations observed at the codon, n a,t is the number of possible transition mutations in the codon that would change the resulting amino acid, n s,t is the number of possible transition mutations that are synonymous, n a,v and n s,v are the equivalent numbers for transversions, and f t and f v are the transition and transversion frequencies, respectively. We calculated an LOD confidence score for a codon to be under positive selection pressure according to the following formula:
NÀi where N is the total number of mutations observed in the codon and q is calculated as follows:
This analysis includes K a /K s values for 2946 individual amino acid mutations (12) at 399 codon positions with LOD scores >2. These data have many applications. For example, strong positive selection (K a /K s > 1) indicates drug-resistance mutations or important fitness effects. Experimental validation data in HIV protease (where causes of drug resistance are well characterized) showed that 19 of 23 known drug resistance codons were correctly predicted by our database, which also accurately predicts the mutant enzyme's activity phenotype (12, 20) . Of the 47 positively selected sites found in the Specialty dataset, 28 were also found in the StanfordUntreated dataset, possibly indicating that those sites can harbor fitness mutations (18) . The database has a simple graphical interface ( Figure 1 ): users can peruse the codonposition selection pressure map directly, click on a position, and inspect detailed tabular results grouped either by codon 
Selection pressure interaction mapping
The massive size of the Specialty dataset makes it possible to measure how selection pressure for one amino acid mutation Y is affected by amino acid mutations at other sites X. Specifically, the database computes K a /K s for mutation Y conditioned on the presence of amino acid mutations at site X versus the absence of any mutation at site X. This 'conditional K a /K s ' (18) calculation is performed as follows:
where N Y a X a and N Y s X a are the numbers of amino acid mutations and synonymous mutations at site Y observed in the presence of amino acid mutations at site X and all other variables retain their previous definitions. Dividing this result by the one obtained in the absence of any mutation at site X to arrive at the 'conditional selection ratio' (18) results in the following expression:
where N Y a X o and N Y s X o are the numbers of samples containing either an amino acid mutation or synonymous mutation at Y and no mutation at X. The LOD score by which we evaluated the significance of apparent positive conditional selection was calculated using the following: where N ¼ N Y a X a þ N Y s X a and q as defined above. For experimental validation, this database correctly predicted 80 of 92 known mutation positive interaction pairs identified in HIV protease by independent experimental studies (P-value ¼ 10 À70 ) (11, 18) . The database again provides a graphical interface ( Figure 2 ) as a 2D heatmap showing all pairwise interactions, which users can click at any position to inspect detailed tabular results.
These data can yield useful insights into HIV drug resistance. For example, the data show a significant interaction between protease site 90 (a known drug resistance mutation site) and site 10 ( Figure 3 ). Amino acid mutations at 90 displayed strong, unconditional positive selection, indicating that they directly cause drug resistance. In contrast, mutations at 10 are negatively selected in the absence of the 90 mutation, but become positively selected in the presence of the 90 mutation (Figure 3) . These results closely match previous experimental studies showing that mutations at 90 cause drug resistance, while mutations at 10 have an accessory effect of compensating for the destabilizing effect of mutations at 90 (21) . Thus, our database can help users by providing information that can distinguish primary drug-resistance mutations from accessory mutations (18) . Users can navigate through links on every result page, to see mutations that strongly select for a given mutation, mutations that are strongly selected for by this mutation, or links to the Stanford (22) and Los Alamos HIV databases (23) giving further information about mutations at this site.
Comparison between the independent datasets in the database can shed additional light on such questions. For example, users can assess whether positively selected mutations in the Specialty dataset are really due to drug resistance, by comparing with the Stanford-Treated and Stanford-Untreated datasets. As shown in Figure 3b and c, the Stanford-Treated data strongly corroborate the Specialty result, while the Stanford-Untreated data show that 90 is indeed involved in drug resistance; it becomes strongly negatively selected in the absence of drug treatment. These data can help users distinguish genuine drug-treatment mutations from those that affect phenotype in other ways, e.g. interactions with the host immune system. Detailed analysis of these datasets demonstrates that the K a /K s results are highly reproducible: independent datasets from different sets of patients show strong quantitative agreement (18) .
FUTURE ADDITIONS
We are currently working to add new data and features to the database. We will add a number of new datasets to the database. First, we will add data for additional HIV genes, such as the env gene, which is important for HIV immune evasion (24) ; although these datasets have smaller numbers of sequences, our analysis has shown that useful K a /K s mapping information can be obtained from such counts. Second, we will analyze mutation data from patients under specific drug-treatment to compare selection pressures caused by different drugs. Third, we will add datasets for other HIV subtypes (e.g. subtype C) to reveal, where selection pressure patterns appear to be consistent with those seen in subtype B (allowing diagnostic criteria from subtype B to be applied to other subtypes) versus where there are important differences. Fourth, we will add a new very large dataset for the Hepatitis C core gene, consisting of approximately 60 000 samples, generously donated by Specialty Laboratories. Lastly, we will add new analyses and graphical interfaces to the database, including phylogenetic analysis and clickable pathway diagrams.
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